Also regarding concerns of oncogenicity, DNMT1 is highly validated as a molecular target to prevent and treat cancer, offering a p53-independent mechanism of action distinct from conventional anti-metabolite therapy and preserving normal dividing cells (excellent therapeutic index) [43,51–54,76,99–103] (reviewed in [104]). This evidence concerns the gene TP53 and cancer.